Taxonomy

CMTA’s CRISPR Research Initiative Advances for CMT1A and CMT1B

The Charcot-Marie-Tooth Association (CMTA) continues its mission to accelerate research

Your Participation Matters: Join the CMT2S Research Study

CMT2S: A Potential New Treatment on the Horizon Charcot-Marie-Tooth Disease

CMTA’s Strategic Investment Advances Research for CMT1A and CMT1B

The Charcot-Marie-Tooth Association (CMTA) continues its mission to accelerate research

CMTA Supports the Accelerating Kids’ Access to Care Act (H.R.4758 / S.2372)

THE CHARCOT-MARIE-TOOTH ASSOCIATION SUPPORTS THE ACCELERATING KIDS’ ACCESS TO CARE

Mindset Strategies for Kids and Teens with CMT

Growing up with a disability presents layers of challenges at

Exploring New Therapeutic Pathways for CMT1B: UPR Activation

Researchers at the Ospedale San Raffaele (OSR) Scientific Institute in

Advancing the Understanding of CMT2A and CMT2F: A Call to Beat CMT

The Charcot-Marie-Tooth Association (CMTA), through its Strategy To Accelerate Research

Let’s Beat CMT – 2024 CMT Awareness Month

#LetsBeatCMT is a social media initiative during CMT Awareness Month

CMTA-STAR Alliance Partner Actio Biosciences Receives FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Their Treatment in Development for CMT2C

The Charcot-Marie-Tooth Association (CMTA) is pleased to share exciting news

CMTA Alliance Partner Applied Therapeutics Plans to Submit an NDA for CMT-SORD, a Potential First Approval for the Treatment of any type of CMT

The Charcot-Marie-Tooth Association (CMTA) is pleased to share exciting news